Pediatric acute graft-versus-host disease prophylaxis and treatment: surveyed real-life approach reveals dissimilarities compared to published recommendations.

Transplant International : Official Journal of the European Society for Organ Transplantation
Anita LawitschkaEuropean Society for Blood, Marrow Transplantation (EBMT) Pediatric Diseases Working Party

Abstract

Pediatric allogeneic hematopoietic cell transplantation (HCT) practices differ from those of adults, particularly the heterogeneity of transplantable nonmalignant diseases and the lower incidence of graft-versus-host disease (GVHD). Several guidelines regarding the management of acute (a) GVHD in adult HCT have been published. We aimed to capture the real-life approaches for pediatric aGVHD prophylaxis/treatment, and data from 75/193 (response rate 39%) EBMT centers (26 countries) were included, representing half (48%) of the pediatric EBMT-HCT activity. Results with ≥75% approval from respondents (74/75) for GVHD prophylaxis after myeloablative HCT for malignancies partially contradict published guidelines: Single-agent cyclosporine A (CsA) was used for matched sibling donor HCT in 47%; blood CsA levels were reported lower; the relapse risk in malignant diseases influenced GVHD prophylaxis with early withdrawal of CsA; distinct longer duration of CsA was employed in nonmalignant diseases. Most centers used additional anti-thymocyte globulin for matched unrelated and mismatched donor HCT, but not for matched siblings. Regarding prophylaxis in nonmyeloablative conditioning (mainly for nonmalignant diseases), responses showed bro...Continue Reading

References

Sep 12, 2000·Bone Marrow Transplantation·C PetersUNKNOWN International BFM Study Group--Subcommittee Bone Marrow Transplantation (IBFM-SG)
Apr 13, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ifeyinwa OsunkwoMitchell S Cairo
Oct 16, 2007·Bone Marrow Transplantation·D A Jacobsohn
Feb 11, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stella M DaviesNancy A Kernan
Apr 19, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul J MartinPaul A Carpenter
Apr 27, 2012·British Journal of Haematology·Fiona L DignanUNKNOWN British Society for Blood and Marrow Transplantation
Jul 10, 2012·Expert Opinion on Pharmacotherapy·Andrew R Rezvani, Rainer F Storb
Feb 5, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel WolffHildegard T Greinix
May 2, 2014·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Sergio RutellaFranco Locatelli
Jun 25, 2014·Nature Reviews. Clinical Oncology·Sung Won Choi, Pavan Reddy
Dec 9, 2014·PloS One·Panayiotis D ZiakasEleftherios Mylonakis
Dec 24, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Katharine OfferPrakash Satwani
Jul 18, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Elisabetta CaloreChiara Messina
Jan 26, 2018·Bone Marrow Transplantation·D WolffK R Schultz
Jun 7, 2018·Bone Marrow Transplantation·Helene M SchoemansUNKNOWN EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (Natio

❮ Previous
Next ❯

Citations

Sep 18, 2020·Pediatric Blood & Cancer·Riccardo MasettiAndrea Pession

❮ Previous
Next ❯

Software Mentioned

SPSS Statistics
R
Excel

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
John F TisdaleRiccardo Saccardi
Handbook of Experimental Pharmacology
R Admiraal, J J Boelens
Advances in Cell and Gene Therapy
Adam R Bryant, Miguel-Angel Perales
© 2021 Meta ULC. All rights reserved